Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022;399:629–55.

Article  CAS  Google Scholar 

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–27.

Article  PubMed  Google Scholar 

Martin A, Fahrbach K, Zhao Q, Lodise T. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to enterobacteriaceae: results of a systematic literature review and meta-analysis. Open Forum Infect Dis. 2018;5:ofy150.

Article  PubMed  PubMed Central  Google Scholar 

Kempf M, Arhin FF, Stone G, Utt E. Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019. J Glob Antimicrob Resist. 2022;31:239–47.

Article  CAS  PubMed  Google Scholar 

La Bella G, Lopizzo T, Lupo L, Angarano R, Curci A, Manti B, et al. In vitro activity of ceftazidime/avibactam against carbapenem-nonsusceptible Klebsiella penumoniae isolates collected during the first wave of the SARS-CoV-2 pandemic: a Southern Italy, multicenter, surveillance study. J Glob Antimicrob Resist. 2022;31:236–8.

Article  PubMed  PubMed Central  Google Scholar 

Tsai CH, Lee NY, Chao CM, Chen CC, Lai CC, Ho CH, et al. Emergence and dissemination of multidrug-resistant escherichia coli ST8346 coharboring bla(NDM-5) and bla(OXA-181) in Southern Taiwan, 2017–2021. J Infect Public Health. 2023;16:1675–81.

Article  PubMed  Google Scholar 

Wise MG, Karlowsky JA, Lemos-Luengas EV, Valdez RR, Sahm DF. Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the atlas surveillance program in 2015–2020. Braz J Infect Dis. 2023;27: 102759.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wise MG, Karlowsky JA, Mohamed N, Kamat S, Sahm DF. In vitro activity of aztreonam-avibactam against enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and eurasia for the atlas global surveillance program in 2019–2021. Eur J Clin Microbiol Infect Dis. 2023;42:1135–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16:661–73.

Article  CAS  PubMed  Google Scholar 

Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind Phase II trial. J Antimicrob Chemother. 2013;68:1183–92.

Article  CAS  PubMed  Google Scholar 

Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al. Efficacy and safety of ceftazidime-avibactam Plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62:1380–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qin X, Tran BG, Kim MJ, Wang L, Nguyen DA, Chen Q, et al. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. Int J Antimicrob Agents. 2017;49:579–88.

Article  CAS  PubMed  Google Scholar 

Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285–95.

Article  CAS  PubMed  Google Scholar 

Vazquez JA, González Patzán LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28:1921–31.

Article  CAS  PubMed  Google Scholar 

Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: recapture, a phase 3 randomized trial program. Clin Infect Dis. 2016;63:754–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gaibani P, Lewis RE, Volpe SL, Giannella M, Campoli C, Landini MP, et al. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Infect Dis. 2017;65:1–3.

Article  CAS  PubMed  Google Scholar 

Mataracı Kara E, Yılmaz M, Özbek ÇB. In vitro activities of ceftazidime/avibactam alone or in combination with antibiotics against multidrug-resistant Acinetobacter baumannii isolates. J Glob Antimicrob Resist. 2019;17:137–41.

Article  PubMed  Google Scholar 

Gaudereto JJ, PerdigãoNeto LV, Leite GC, RuedasMartins R, do BoasPrado GV, Rossi F, et al. Synergistic effect of ceftazidime-avibactam with meropenem against panresistant, carbapenemase-harboring acinetobacter baumannii and serratia marcescens investigated using time-kill and disk approximation assays. Antimicrob Agents Chemother. 2019. https://doi.org/10.1128/AAC.02367-18.

Article  PubMed  PubMed Central  Google Scholar 

Kroemer N, Martens M, Decousser JW, Grégoire N, Nordmann P, Wicha SG. Evaluation of in vitro pharmacodynamic drug interactions of ceftazidime/avibactam and fosfomycin in escherichia coli. J Antimicrob Chemother. 2023;78:2524–34.

Article  CAS  PubMed  Google Scholar 

Romina PE, Lucía A, Leticia C, Federica F, Pablo Á, Verónica S, et al. In vitro effectiveness of ceftazidime-avibactam in combination with aztreonam on carbapenemase-producing Enterobacterales. J Glob Antimicrob Resist. 2023;35:62–6.

Article  CAS  PubMed  Google Scholar 

Boattini M, Bianco G, Charrier L, Comini S, Iannaccone M, Almeida A, et al. Rapid diagnostics and ceftazidime/avibactam for KPC-producing Klebsiella pneumoniae bloodstream infections: impact on mortality and role of combination therapy. Eur J Clin Microbiol Infect Dis. 2023;42:431–9.

Article  CAS  PubMed  Google Scholar 

Alqahtani H, Alghamdi A, Alobaidallah N, Alfayez A, Almousa R, Albagli R, et al. Evaluation of ceftazidime/avibactam for treatment of carbapenemase-producing carbapenem-resistant Enterobacterales with OXA-48 and/or NDM genes with or without combination therapy. JAC Antimicrob Resist. 2022;4:dlac104.

Article  PubMed  PubMed Central  Google Scholar 

Lin J, Zhang L, Zhou M, Tian X, Chen J, Lu M, et al. Combination therapy of ceftazidime/avibactam for the treatment of patients infected with carbapenem-resistant klebsiella pneumoniae: a multicenter retrospective study. Infect Dis Ther. 2023;12:2165–77.

Article  PubMed  PubMed Central  Google Scholar 

King M, Heil E, Kuriakose S, Bias T, Huang V, El-Beyrouty C, et al. Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant enterobacteriaceae infections. Antimicrob Agents Chemother. 2017;61:10–128.

Article  Google Scholar 

Sousa A, Pérez-Rodríguez MT, Soto A, Rodríguez L, Pérez-Landeiro A, Martínez-Lamas L, et al. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing enterobacteriaceae. J Antimicrob Chemother. 2018;73:3170–5.

Article  CAS  PubMed  Google Scholar 

Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, et al. Efficacy of ceftazidime-avibactam salvage therapy in Patients with infections caused by klebsiella pneumoniae carbapenemase-producing k pneumoniae. Clin Infect Dis. 2019;68:355–64.

Article  CAS  PubMed  Google Scholar 

Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, et al. Ceftazidime-avibactam use for klebsiella pneumoniae carbapenemase-producing k pneumoniae Infections: a retrospective observational multicenter study. Clin Infect Dis. 2021;73:1664–76.

Article  CAS  PubMed  Google Scholar 

Li D, Fei F, Yu H, Huang X, Long S, Zhou H, et al. ceftazidime-avibactam therapy versus ceftazidime-avibactam-based combination therapy in patients with carbapenem-resistant gram-negative pathogens: a meta-analysis. Front Pharmacol. 2021;12: 707499.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fiore M, Alfieri A, Di Franco S, Pace MC, Simeon V, Ingoglia G, et al. Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant Pathogens: a systematic review and network meta-analysis. Antibiotics (Basel). 2020;9:388.

Article  CAS  PubMed  Google Scholar 

Onorato L, Di Caprio G, Signoriello S, Coppola N. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant gram-negative bacteria: a meta-analysis. Int J Antimicrob Agents. 2019;54:735–40.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The Prisma 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:89.

Article  PubMed  PubMed Central  Google Scholar 

Jonathan ACS, Miguel AH, Barnaby CR, Jelena S, Nancy DB, Meera V, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919.

Google Scholar 

Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis Dio. 2023. https://doi.org/10.1093/cid/ciad428.

Article